Table 2 Mortality of patients based on patient condition, carbapenemases type, study region
Subgroup | Number of studies | Sample size | Mortality Rate %(95% CI) | Statistical model |
|---|---|---|---|---|
Pooled mortality | PÂ <Â 0.001 | |||
 CRKP | 62 | 2462 | 42.14 (37.06–47.31) | Random |
 CSKP | 22 | 2239 | 21.12 (16.07–26.79) | Random |
Patient conditions | PÂ <Â 0.001 | |||
 Bloodstream infections | 20 | 722 | 54.30 (47.51–61.02) | Random |
 Urinary tract infections | 8 | 284 | 13.52 (7.50–20.92) | Random |
 Intensive care unit | 12 | 479 | 53.90 (39.44–68.00) | Random |
 Solid organ transplantation | 15 | 362 | 43.13 (32.40–54.16) | Random |
Carbapenemases type | PÂ =Â 0.645 | |||
 KPC-producing Klebsiella pneumoniae | 13 | 302 | 47.66 (38.61–49.51) | Random |
 VIM-producing Klebsiella pneumoniae | 5 | 73 | 46.71 (35.81–57.73) | Random |
Region | PÂ =Â 0.062 | |||
 North America | 23 | 980 | 33.24 (25.08–42.00) | Random |
 South America | 8 | 191 | 46.71 (39.83–53.66) | Fixed |
 Europe | 21 | 860 | 50.06 (41.45–58.62) | Random |
 Asia | 10 | 431 | 44.82 (37.83–51.91) | Random |